Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexobarbital is a barbiturate derivative with hypnotic and sedative effects. It was primarily used in the 1940s and 1950s as an anesthetic for surgery and as a rapid-acting, short-lasting hypnotic. Hexobarbital has a relatively fast onset of action and short duration of effect. Its use in human medicine has largely been replaced by safer alternatives such as thiopental due to difficulties in controlling anesthesia depth. The mechanism of action involves binding to a distinct site on the GABA-A receptor chloride ionophore complex, increasing the duration that the chloride channel remains open. This potentiates GABAergic inhibition in the central nervous system by prolonging post-synaptic inhibitory effects[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hexobarbital.